Shafaq news/ A Covid-19 vaccine developed by Moderna company, has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.

These early results, showed that the vaccine worked to trigger an immune response with mild side effects (fatigue, chills, headache, muscle pain, pain at the injection site).

The vaccine is expected to begin later this month a large Phase 3 trial, which is the final trial stage before regulators consider whether to make the vaccine available or not.

Moderna noted in a press release, on Tuesday, that if all goes well in future studies, "the Company remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021".

Moderna expects to start the company's largest study yet of its Covid-19 vaccine candidate mRNA-1237 on July 27. It's expected to be the first in the United States to begin Phase 3 trials.